NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION
The present disclosure provides a regimen for treating a subject afflicted with prostate cancer by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab. The present disclosure is based on the discovery that the combination of Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab in a specific treatment regimen is a very effective therapy to treat subjects afflicted with prostate cancer.
1 . A treatment regimen for treating prostate cancer in a subject in need thereof, the regimen comprising administering to said subject, as separate pharmaceutical formulations, an effective amount of Talabostat or a pharmaceutically acceptable salt thereof and an effective amount of Pembrolizumab, wherein Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab are administered in one or more treatment cycles and each treatment cycle is of about 21 days duration.
2 . A method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject, as separate pharmaceutical formulations, an effective amount of Talabostat or a pharmaceutically acceptable salt thereof and an effective amount of Pembrolizumab, wherein Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab are administered to the subject in 1, 2 or 3 treatment cycles and each treatment cycle is of about 21 days duration.
3 . (canceled)
4 . (canceled)
5 . The treatment regimen according to claim 1 , wherein the prostate cancer is small cell neuroendocrine prostate cancer (SCNC).
6 . The treatment regimen according to claim 1 , wherein after cessation of treatment the subject maintains a sustained response to progression of prostate cancer.
7 . The treatment regimen according to claim 1 , wherein for each treatment cycle Talabostat or a pharmaceutically acceptable salt thereof is administered on each of days 1 to 14 and Pembrolizumab is administered on day 1.
8 . The method according to claim 2 , wherein for each treatment cycle Talabostat or a pharmaceutically acceptable salt thereof is administered on each of days 1 to 14 and Pembrolizumab is administered on day 1.
9 . The treatment regimen according to claim 1 , wherein Talabostat or a pharmaceutically acceptable salt thereof is administered orally in one or more tablet.
10 . The treatment regimen according to claim 1 , wherein Pembrolizumab is administered by intravenous injection.
11 . The treatment regimen according to claim 1 , wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a total daily dose of from about 0.001 mg/kg to about 0.1 mg/kg.
12 . The treatment regimen according to claim 1 , wherein Pembrolizumab is administered at a total dose of from about 1 mg/kg to about 10 mg/kg per day.
13 . The treatment regimen according to claim 1 , wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a total daily dose of from about 0.4 mg to about 0.6 mg.
14 . The treatment regimen according to claim 1 , wherein Pembrolizumab is administered at a total dose of from about 100 mg to about 500 mg per day.
15 . The treatment regimen according to claim 1 , wherein Pembrolizumab is administered at a total dose of about 200 mg per day.
16 . The treatment regimen according to claim 1 , wherein the total daily dose of Talabostat in cycle 1 is lower than the total daily dose of Talabostat or a pharmaceutically acceptable salt thereof in one or more subsequent cycles.
17 . The treatment regimen according to claim 1 , wherein Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab are administered to the subject in one or more treatment cycles, where each treatment cycle is of about 21 days duration, and for each treatment cycle Talabostat or a pharmaceutically acceptable salt thereof is administered on each of days 1 to 14 and Pembrolizumab is administered on day 1.
18 . The treatment regimen or method according to claim 17 , wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a total daily dose of from about 0.4 mg to about 0.6 mg.
19 . The treatment regimen or method according to claim 18 , wherein the total daily dose of Talabostat or a pharmaceutically acceptable salt thereof in cycle 1 is lower than the total daily dose of Talabostat in one or more subsequent cycles.
20 . The treatment regimen according to claim 1 , wherein Talabostat or a pharmaceutically acceptable salt thereof is Talabostat mesylate.
21 . A treatment regimen for treating prostate cancer in a subject in need thereof, the regimen comprising administering to the subject Talabostat mesylate and Pembrolizumab in one or more treatment cycles, where each treatment cycle is of about 21 days duration, and for each treatment cycle Talabostat is administered on each of days 1 to 14 and Pembrolizumab is administered on day 1, wherein Talabostat mesylate is administered as one or more tablets to provide a total daily dose of Talabostat of from about 0.4 mg to about 0.6 mg and Pembrolizumab is administered as a single intravenous injection to provide a dose of from about 100 mg to about 500 mg per day.